Skip to content
For US Healthcare Professionals Patient Site

How RMS Patients Experience LEMTRADA

See ways your patients may align with the real-life LEMTRADA users

Access the patient profiles below or use the filter tool to select profiles according to characteristics relevant to your RMS patients.

Clear Selection
Select Gender
Select Age
Select Ethnicity
Select Prior Treatment(s)
Picture of LEMTRADA patient Kim.
Kim
44
MAGNOLIA, TX
RMS TREATMENT HISTORY
 

2 prior DMTs:

1 injectable and

1 oral therapy

View Profile Details
Picture of LEMTRADA patient Luis.
Luis
38
EL PASO, TX
RMS TREATMENT HISTORY
 

2 prior DMTs:

2 injectables

View Profile Details
Picture of LEMTRADA patient Ginny.
Ginny
38
PHOENIX, AZ
RMS TREATMENT HISTORY
 

5 prior DMTs:

2 injectables, 2 oral treatments,

and 1 infusion therapy

View Profile Details
Picture of LEMTRADA patient Charles.
Charles
23
MARSHALL, MN
RMS TREATMENT HISTORY
 

1 prior DMT:

1 injectable therapy

for 1 year

View Profile Details
Picture of LEMTRADA patient Ashley.
Ashley
38
RIVER FOREST, IL
RMS TREATMENT HISTORY
 

4 prior DMTs:

3 injectables and

1 infusion therapy

View Profile Details
Picture of LEMTRADA patient Donnie.
Donnie
48
WINCHESTER, KY
RMS TREATMENT HISTORY
 

4 prior DMTs:

2 injectables, 1 oral therapy,

and 1 infusion treatment

View Profile Details

No patient profile results match these criteria.

Please try again with different selections.

RMS Patients Are Determined

Hear video testimonies from LEMTRADA patients taking an active role in their treatment.

INDICATION

LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Limitations of Use: LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: AUTOIMMUNITY, INFUSION REACTIONS, STROKE AND MALIGNANCIES

CONTRAINDICATIONS

LEMTRADA is contraindicated in patients:

WARNINGS AND PRECAUTIONS

Most Common Adverse Reactions

In controlled clinical trials, the most common adverse reactions (incidence ≥10% and >interferon beta-1a) with LEMTRADA vs interferon beta-1a were: rash (53% vs 6%), headache (52% vs 23%), pyrexia (29% vs 9%), nasopharyngitis (25% vs 19%), nausea (21% vs 9%), urinary tract infection (19% vs 8%), fatigue (18% vs 13%), insomnia (16% vs 15%), upper respiratory tract infection (16% vs 13%), herpes viral infection (16% vs 3%), urticaria (16% vs 2%), pruritus (14% vs 2%), thyroid gland disorders (13% vs 3%), fungal infection (13% vs 4%), arthralgia (12% vs 9%), pain in extremity (12% vs 9%), back pain (12% vs 8%), diarrhea (12% vs 6%), sinusitis (11% vs 8%), oropharyngeal pain (11% vs 5%), paresthesia (10% vs 8%), dizziness (10% vs 5%), abdominal pain (10% vs 5%), flushing (10% vs 4%), and vomiting (10% vs 3%).

Use in Specific Populations

Physicians are encouraged to report pregnancies by calling 1-800-745-4447, option 2. Antibodies, including anti-CD52 and autoantibodies, may be transferred from the mother to the fetus during pregnancy. Placental transfer of anti-thyroid antibodies resulting in neonatal Graves’ disease has been reported.

Safety and effectiveness in pediatric patients less than 17 years of age have not been established. Use of LEMTRADA is not recommended in pediatric patients due to the risks of autoimmunity and infusion reactions, stroke, and because it may increase the risk of malignancies.

Please see full Prescribing Information, including Boxed WARNING.

Indication

LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Limitations of Use: LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: AUTOIMMUNITY, INFUSION REACTIONS, STROKE AND MALIGNANCIES

  • LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia and anti-glomerular basement membrane (anti-GBM) disease. Monitor complete blood counts with differential, serum
Alternate Text